Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Cellmark Acquires Strand's Paternity and Immigration Testing Business

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Orchid Cellmark said today that it has bought Strand Analytical Laboratories’ paternity and immigration DNA testing business unit for an undisclosed sum.

Indianapolis-based Strand provides forensic, medical, and paternity testing services.

This deal gives Orchid Cellmark Strand’s government paternity, private paternity, and immigration accounts, which last year had revenues of around $450,000.

Orchid Cellmark, headquartered in Princeton, NJ, said that it plans to support these new accounts from its Dayton, Ohio, paternity services facility. Strand will continue to support the clients for its other DNA testing business units.

"While Strand’s paternity business is relatively small in size, the acquisition is consistent with our strategy to grow revenues," Orchid Cellmark CEO and President Thomas Bologna said in a statement.

Financial terms of the agreement were not released.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more